Abstract
Carnosine is a dipeptide expressed in both the central nervous system and periphery. Several biological functions have been attributed to carnosine, including as an anti-inflammatory and antioxidant agent, and as a modulator of mitochondrial metabolism. Some of these mechanisms have been implicated in the pathophysiology of coronavirus disease-2019 (COVID-19). COVID-19 is caused by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2). The clinical manifestation and recovery time for COVID-19 are variable. Some patients are severely affected by SARS-CoV-2 infection and may experience respiratory failure, thromboembolic disease, neurological symptoms, kidney damage, acute pancreatitis, and even death. COVID-19 patients with comorbidities, including diabetes, are at higher risk of death. Mechanisms underlying the dysfunction of the afflicted organs in COVID-19 patients have been discussed, the most common being the so-called cytokine storm. Given the biological effects attributed to carnosine, adjuvant therapy with this dipeptide could be considered as supportive treatment in patients with either COVID-19 or long COVID.
Introduction
In 2019 the coronavirus disease-2019 (COVID-19) emerged in China (). COVID-19 is caused by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2; ). SARS-CoV-2 has quickly spread around the world with devastating consequences (). The clinical manifestation and recovery time for COVID-19 are variable (Wen et al., 2020; Wiersinga et al., 2020). Most infected patients remain asymptomatic or present mild symptoms, including a flu-like condition consisting of nasal congestion, loss of taste and smell, fatigue, and fever (Wiersinga et al., 2020; Zhou et al., 2020). However, some patients are more severely affected by SARS-CoV-2 infection and may experience respiratory failure, thromboembolic disease, neurological symptoms, kidney damage, acute pancreatitis, and even death (Piroth et al., 2020; Wiersinga et al., 2020; Ye et al., 2020). Mechanisms underlying the dysfunction of the afflicted organs in COVID-19 patients have been discussed, the most common being the so-called cytokine storm include elevated levels of tumor necrosis factor-alpha (TNF-α) and interleukin 6 (). At the time of discharge from intensive care units, cytokines levels of COVID-19 patients have normally returned to the physiological range (Rodriguez et al., 2020; Wen et al., 2020). Researchers and health professionals are under pressure to reuse, identify and develop new drugs for this global emergency (Sahebnasagh et al., 2020). Based on the biological effects attributed to carnosine, it is suggested this dipeptide can be considered a palliative therapeutic with respect to COVID-19 and long COVID.
Long-Term Complications
The number of patients recovered from SARS-CoV-2 infection with diseases associated with long COVID is unprecedented and unpredictable (Rando et al., 2021). Long COVID symptoms include physical pain, fatigue, dyspnea, gastrointestinal symptoms, headaches, and memory and psychological disturbances (Mahase, 2020; Mandal et al., 2020; Yelin et al., 2020). These symptoms can evolve over weeks/months following SARS-CoV-2 infection (Mahase, 2020). Whilst some patients report residual COVID-19 symptoms, others may develop new symptoms or new diseases (such as diabetes) long after the initial infection (; Korompoki et al., 2021).
Carnosine and Its Metabolism
Carnosine is a dipeptide composed of β-alanine and L-histidine (). It is expressed in both the central nervous system (CNS) and periphery including skeletal muscle (Nagai and Suda, 1998; ; ). Carnosine is synthesized by carnosine synthase [EC 6.3.2.11], and its hydrolysis is catalyzed by serum carnosinase (CN1) [EC 3.4.13.20] and/or cytosolic carnosinase (CN2) [EC 3.4.13.3] (Lenney et al., 1982; Lenney, 1990; Teufel et al., 2003). Effective transport of this dipeptide in different cell types occurs via peptide transporter 2 (PepT 2; Xiang et al., 2006; Lopachev et al., 2021).
Biological Actions of Carnosine
Recent studies have revealed that carnosine is present in human erythrocytes and that acetyl-carnosine (resistant to serum carnosine attack) is present in human serum, the concentration of each decrease with age (). Other studies have revealed that very low levels of acetyl-carnosine are strongly associated with human frailty (), and the blood of patient suffering from age-related macular degeneration contained very low amounts of carnosine (). So far, several biological functions have been attributed to carnosine, including as an anti-inflammatory () and antioxidant () agent, and as a modulator of mitochondrial metabolism (Macarini et al., 2014; Shen et al., 2014; Macedo et al., 2016). Supported by the myriad of effects reported, carnosine has been suggested to decelerate aging symptoms (), as well as for the treatment of other diseases, including cardiovascular disease (Menon et al., 2021), neurodegenerative diseases (), and diabetes (). The latter is mainly supported by its hypoglycemic () and anti-glycation effects (Pepper et al., 2010; ). Additionally, carnosine’s ability to partially suppress glycolysis in a variety of cell types from yeast to tumor cells (Renner et al., 2010; ; ) [perhaps by altering mRNA translation (Son et al., 2008)] may also help to explain the dipeptide’s beneficial effects toward SARS-Cov-2 viral infectivity (). Indeed, such infection usually induces an upregulation of glycolysis in the infected tissue (). While carnosine might exert therapeutic activity toward COVID-19 virus infection (Lopachev et al., 2020; Saadah et al., 2020; ), the possibility that the dipeptide could be protective toward long COVID has not been thoroughly examined.
Carnosine and Diabetes
The possible application of carnosine for the treatment of diabetes mellitus has been previously discussed (). Carnosine supplementation mitigates the elevation of glucose, triglycerides, and TNF-α levels in patients with type-2 diabetes (), and/or in overweight or obese pre-diabetic patients (Liu et al., 2015; ). In this scenario, carnosine was shown to suppress glycolysis in different cell types (). Carnosine also enhances the clearance of a variety of deleterious aldehydes, such as formaldehyde, methylglyoxal and the glycolytic intermediates dihydroxyacetone phosphate and glyceraldehyde-3-phosphate. All of these reactive aldehydes can modify (glycate) proteins, including mitochondrial proteins (; ; ). Methylglyoxal is responsible for many macromolecular modifications associated with secondary complications of type-2 diabetes, for instance enhanced protein glycation ().
Diabetic Patients at Increased Risk of Worse Coronavirus Disease-2019 Symptoms
Coronavirus disease-2019 patients with comorbidities are at high risk of death (Piroth et al., 2020). The main complicating conditions include hypertension, cardiovascular disease, obesity, chronic obstructive pulmonary disease, and diabetes (; Wu and McGoogan, 2020). Diabetes is linked to metabolic and macro/microvascular complications that increase morbidity and mortality in different viral infections (Rasheed et al., 2019). SARS-CoV-2 entry into the target cell is facilitated by the connection from the spike protein to a cellular receptor, attaching the virus to the surface of infected cells (). Cellular receptors known to be involved in SARS-CoV-2 infection are the angiotensin-converting enzyme 2 (ACE2) and the transmembrane serine protease (TMPRSS2 and TMPRSS4; Zhang et al., 2003; ). Multiple organs are susceptible to SARS-CoV-2 infection, such as the lungs, digestive tract, kidneys, heart, brain, and pancreas (; Puelles et al., 2020). ACE2 is upregulated in patients with cardiovascular disease, hypertension, and diabetes (Pollard et al., 2020). Diabetic patients are at higher risk for the cytokine storm secondary to the pro-inflammatory state triggered by COVID-19 (), as well as of diabetic ketoacidosis and mortality (Lim et al., 2020). The cytokine storm also leads to peripheral insulin resistance () and disrupts pancreatic β-cells functioning, inhibiting insulin secretion (Mehta et al., 2020). The pancreatic damage and hyperglycemia are further stimulated by the direct invasion of SARS-CoV-2 to the pancreas (Zhang et al., 2003). Taken together, these effects contribute to the development of hyperglycemia in COVID-19 patients (Mehta et al., 2020) and potentially induce type 1 diabetes during the long COVID period (Lim et al., 2020). While we strive to understand how COVID-19 induces diabetes or aggravates the existing disease, it is mandatory to maintain long-term follow-up of these patients.
Recovered Patients at Increased Risk of Developing Diabetes
The term “long COVID” refers to patients with a post-acute COVID-19 (defined as the presence of symptoms 3+ weeks from the onset of symptoms) or chronic COVID-19 (symptoms 12+ weeks; Rubin, 2020; Korompoki et al., 2021). Long-term hyperglycemia in COVID-19 induces oxidative stress, contributing to the development of insulin resistance and dysregulation of pancreatic β-cells (). Many cases of pancreatitis have been reported in COVID-19 patients (; ; Wang et al., 2020). Pancreatic damage and hyperglycemia may evolve over weeks or months following SARS-CoV-2 infection (Mahase, 2020). In this scenario, reports of late diabetes (and also other complications) in patients recovered from SARS-CoV-2 infection have recently emerged (Mahase, 2020; Morieri et al., 2020; Korompoki et al., 2021).
Carnosine and Other Coronavirus Disease-2019 Complications
Carnosine was shown to lower the affinity between ACE2 and the spike protein from SARS-CoV-2 (Saadah et al., 2020). So far, no further actions of carnosine on this mechanism have been reported, nor on the interaction of the virus with host cells, neither on viral lifespan. However, given its antioxidant and anti-inflammatory properties (; Ooi et al., 2020; Scuto et al., 2020), carnosine may attenuate the cytokine storm in COVID-19 patients. Carnosine could also restrain other COVID-19 complications.
A hypercoagulatory state may contribute to an increased mortality in COVID-19 (Mucha et al., 2020). This dysregulated coagulation can be induced by methylglyoxal, which causes post-synthetic protein glycation in diabetics, including the glycation of the anticoagulants anti-thrombin III () and plasminogen (). Carnosine can inhibit protein glycation and possibly eliminate methylglyoxal, thereby suppressing the anticoagulant modification induced by this reactive carbonyl ().
The elderly individuals over 50 years old are particularly susceptible to worse complications (e.g., severe pneumonia) and death following coronavirus infections (), which is also true for COVID-19 (). The immune system is impaired during the aging process, rendering the elderly more susceptible to SARS-CoV-2 infection (Wu and McGoogan, 2020). In this context, carnosine’s putative anti-aging properties delayed senescence, lifespan extension, and rejuvenation of cultured human and rodent cells (McFarland and Holliday, 1994; ; Yuneva et al., 2002; Stvolinsky et al., 2010; ; ) suggest that the dipeptide could be explored. Cellular aging and cell senescence are associated with telomere shortening () and increases of transforming growth factor-β (TGF-β) signaling and Smad3 expression (; ). In cultured human cells, carnosine slows telomeres shortening (Shao et al., 2004) and suppresses TGF-β production and signaling, possibly involving inhibition of the Smad2/3 pathway (Köppel et al., 2011). Carnosine can up-regulate coenzyme Q10 synthesis (Schwank-Xu et al., 2021), thereby stimulating mitochondrial activity and contributing to a less aged cellular physiological state. Since CN1 expression increases throughout development (Lenney et al., 1982), a progressive decline in serum carnosine concentrations is observed in elderly humans (Stuerenburg and Kunze, 1999; Tallon et al., 2007) and a correlation between increased CN1 expression and decreased carnosine levels in specific rat brain regions has been detected (). To date, there is no report indicating alterations on carnosine metabolism enzymes elicited by SARS-CoV-2. The brain is an important organ in the clinical presentation of COVID-19. Long COVID patients may also present long lasting neurological symptoms, including the brain fog, hallucinations, double vision, numbness in their limbs or face, disorientation and difficulty concentrating. These symptoms may persist even after 5 months of SARS-CoV-2 infection (Karuppan et al., 2021). Over the last decades, carnosine has been widely suggested as a contributor to brain health (; ; ; Kawahara et al., 2018, 2020; ; Schön et al., 2019).
Administration of Carnosine/Acetyl-Carnosine
Dietary administration of carnosine is hampered by the presence of serum carnosinase in humans. Previous suggestions have included the nasal route especially as this could raise carnosine levels in the olfactory bulb and so perhaps alleviate cognitive impairment, anxiety and long COVID-associated brain fog (Ma and Vervoort, 2020). The presence of the carnosine in the airways may also locally suppress infection. There are no reported studies on the possible efficacy of dietary acetyl-carnosine toward almost any age-related condition, with the exception of lenticular cataracts where the direct application of acetyl-carnosine in solution has been proposed as a therapeutic agent ().
Discussion
The COVID-19 pandemics is a challenging scenario for the global population, researchers, and front-line health professionals (Sahebnasagh et al., 2020). The molecular and cellular bases of COVID-19 are heterogeneous and there is an urge for its complete elucidation. Due to the lack of complete SARS-CoV-2 immunity and of comprehensive vaccination strategy, the unpredictable clinical results of COVID-19 are concerning (; Ma et al., 2020; Ma and Vervoort, 2020). Long COVID is a condition that affects a wide range of patients (Rubin, 2020), which is severely challenging the entire healthcare system. Nevertheless, immunized patients are less likely to develop long COVID compared to the un-immunized (). The long-lasting symptomatology can result in chronic morbidity (Shah et al., 2021), including the development of diabetes (Korompoki et al., 2021). The emergence of new COVID-19 variants threatens us with an increase in the proportion of patients suffering from long COVID. Here, we have summarized the available evidence indicating the potential role of carnosine/acetyl-carnosine in ameliorating long-term complications of COVID-19 and diabetes (Figure 1). Whenever possible, the presence of serum acetyl-carnosine and erythrocyte carnosine levels should be measured to determine whether the levels of these peptides could be predictive of morbidity or mortality, and whether raising their levels has any beneficial effects on clinical course and survival. Given the biological effects attributed to carnosine, intranasal adjuvant therapy with this dipeptide could be considered as supportive treatment in patients with either COVID-19 or long COVID.
FIGURE 1
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Statements
Author contributions
FD and GF contributed to the design, overall collection of information, and writing and final revision of the manuscript. AH was involved in the data collection for diabetes and other long COVID complications, writing and final revision of the manuscript. All authors contributed to the article and approved the submitted version.
Funding
Grants from Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ) and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) supported this work. FD is recipient of a CNPq Ph.D. fellowship. GF has research fellowships from CNPq and FAPERJ.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
Abdul-HadiM. H.NajiM. T.ShamsH. A.SamiO. M.Al-HarchanN. A.Al-KuraishyH. M.et al (2020). Oxidative stress injury and glucolipotoxicity in type 2 diabetes mellitus: the potential role of metformin and sitagliptin.Biomed. Biotechnol. Res. J.4:166. 10.4103/bbrj.bbrj_7_20
2
Al-KuraishyH. M.Al-GareebA. I. (2020). From SARS-CoV to nCoV-2019: ruction and argument.Arch. Clin. Infect. Dis.15:e102624. 10.5812/archcid.10262
3
AnandE. R.MajorC.PickeringO.NelsonM. (2020). Acute pancreatitis in a COVID-19 patient.Br. J. Surg.107;e182. 10.1002/bjs.11657
4
AntonelliM.PenfoldR. S.MerinoJ.SudreC. H.MolteniE.BerryS.et al (2021). Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study.Lancet Infect. Dis.2243–55. 10.1016/S1473-3099(21)00460-6
5
ApicellaM.CampopianoM. C.MantuanoM.MazoniL.CoppelliA.Del PratoS. (2020). COVID-19 in people with diabetes: understanding the reasons for worse outcomes.Lancet Diabetes Endocrinol.8782–792. 10.1016/S2213-8587(20)30238-2
6
BalionC. M.BensonC.RainaP. S.PapaioannouA.PattersonC.IsmailaA. S. (2007). Brain type carnosinase in dementia: a pilot study.BMC Neurol.7:38. 10.1186/1471-2377-7-38
7
BarcaA.GattiF.SpagnoloD.IppatiS.VetrugnoC.VerriT. (2018). Responsiveness of carnosine homeostasis genes in the pancreas and brain of streptozotocin-treated mice exposed to dietary carnosine.Int. J. Mol. Sci.19:1713. 10.3390/ijms19061713
8
BaugéC.DuvalE.OllitraultD.GirardN.LeclercqS.GaléraP.et al (2013). Type II TGFβ receptor modulates chondrocyte phenotype.Age351105–1116. 10.1007/s11357-012-9433-7
9
BedfordJ.EnriaD.GieseckeJ.HeymannD. L.IhekweazuC.KobingerG.et al (2020). COVID-19: towards controlling of a pandemic.Lancet3951015–1018.
10
BojkovaD.KlannK.KochB.WideraM.KrauseD.CiesekS.et al (2020). Proteomics of SARS-CoV-2-infected host cells reveals therapy targets.Nature583469–472. 10.1038/s41586-020-2332-7
11
BoldyrevA. A.AldiniG.DeraveW. (2013). Physiology and pathophysiology of carnosine.Physiol. Rev.931803–1845. 10.1152/physrev.00039.2012
12
BonfantiL.PerettoP.De MarchisS.FasoloA. (1999). Carnosine-related dipeptides in the mammalian brain.Prog. Neurobiol.59333–353. 10.1016/S0301-0082(99)00010-6
13
BongC. L.BrasherC.ChikumbaE.McDougallR.Mellin-OlsenJ.EnrightA. (2020). The COVID-19 pandemic: effects on low- and middle-income countries.Anesth. Analg13186–92. 10.1213/ANE.0000000000004846
14
CarusoG.FrestaC. G.MussoN.GiambirtoneM.GrassoM.SpampinatoS. F.et al (2019). Carnosine prevents Aβ-induced oxidative stress and inflammation in microglial cells: a key role of TGF-β1.Cells8:64. 10.3390/cells8010064
15
ChaleckisR.MurakamiI.TakadaJ.KondohH.YanagidaM. (2016). Individual variability in human blood metabolites identifies age-related differences.Proc. Natl. Acad. Sci.U.S.A.1134252–4259. 10.1073/pnas.1603023113
16
Chao de la BarcaJ. M.Rondet-CourbisB.FerréM.MullerJ.BuissetA.LeruezS.et al (2020). A plasma metabolomic profiling of exudative age-related macular degeneration showing carnosine and mitochondrial deficiencies.J. Clin. Med.9:631. 10.3390/jcm9030631
17
ChilukuriH.KulkarniM. J.FernandesM. (2018). Revisiting amino acids and peptides as anti-glycation agents.Medchemcomm9614–624. 10.1039/c7md00514h
18
CirulliE. T.BarrettK. M. S.RiffleS.BolzeA.NeveuxI.DabeS.et al (2020). Long-term COVID-19 symptoms in a large unselected population.medRxiv [Preprint] 10.1101/2020.10.07.20208702
19
ColzaniM.De MaddisD.CasaliG.CariniM.VistoliG.AldiniG.et al (2016). Reactivity, selectivity, and reaction mechanisms of aminoguanidine, hydralazine, pyridoxamine, and carnosine as sequestering agents of reactive carbonyl species: a comparative study.Chem. Med. Chem.111778–1789. 10.1002/cmdc.201500552
20
DaoustJ. F. (2020). Elderly people and responses to COVID-19 in 27 Countries.PLoS One15:e0235590. 10.1371/journal.pone.0235590
21
de CourtenB.JakubovaM.de CourtenM. P.KukurovaI. J.VallovaS.KrumpolecP.et al (2016). Effects of carnosine supplementation on glucose metabolism: pilot clinical trial.Obesity241027–1034. 10.1002/oby.21434
22
DoyleK. P.CekanaviciuteE.MamerL. E.BuckwalterM. S. T. G. F. (2010). β signaling in the brain increases with aging and signals to astrocytes and innate immune cells in the weeks after stroke.J. Neuroinflammation7:62. 10.1186/1742-2094-7-62
23
FeehanJ.de CourtenM.ApostolopoulosV.de CourtenB. (2021). Nutritional interventions for COVID-19: a role for carnosine?Nutrients13:1463. 10.3390/nu13051463
24
FrestaC. G.FidilioA.LazzarinoG.MussoN.GrassoM.MerloS.et al (2020). Modulation of pro-oxidant and pro-inflammatory activities of M1 macrophages by the natural dipeptide carnosine.Int. J. Mol. Sci.21:776. 10.3390/ijms21030776
25
GallantS.SemyonovaM.YunevaM. (2000). Carnosine as a potential anti-senescence drug.Biochemistry65866–868.
26
GavriatopoulouM.KorompokiE.FotiouD.Ntanasis-StathopoulosI.PsaltopoulouT.KastritisE.et al (2020). Organ-specific manifestations of COVID-19 infection.Clin. Exp. Med.20493–506. 10.1007/s10238-020-00648-x
27
GhoshA.GuptaV.MisraA. (2020). COVID19 induced acute pancreatitis and pancreatic necrosis in a patient with type 2 diabetes.Diabetes Metab. Syndr. Clin. Res. Rev.142097–2098. 10.1016/j.dsx.2020.10.008
28
GugliucciA. (2003). A practical method to study functional impairment of proteins by glycation and effects of inhibitors using current coagulation/fibrinolysis reagent kits.Clin. Biochem.36155–158. 10.1016/s0009-9120(02)00442-3
29
HendrenN. S.DraznerM. H.BozkurtB.CooperL. (2020). Description and proposed management of the acute COVID-19 cardiovascular syndrome.Circulation1411903–1914. 10.1161/CIRCULATIONAHA.120.047349
30
HipkissA. R. (2007). Could carnosine or related structures suppress Alzheimer’s disease?J. Alzheimers Dis.11229–240. 10.3233/jad-2007-11210
31
HipkissA. R. (2011). Energy metabolism, proteotoxic stress and age-related dysfunction – protection by carnosine.Mol. Aspects Med.32267–278. 10.1016/j.mam.2011.10.004
32
HipkissA. R. (2017). Depression, diabetes and dementia: formaldehyde may be a common causal agent; could carnosine, a pluripotent peptide, be protective?Aging Dis.8128–130. 10.14336/AD.2017.0120
33
HipkissA. R. (2020). COVID-19 and senotherapeutics: any role for the naturally occurring dipeptide carnosine?Aging Dis.11737–741. 10.14336/AD.2020.0518
34
HipkissA. R.BrownsonC. (2000). A possible new role for the anti-ageing peptide carnosine.Cell Mol. Life Sci.57747–753. 10.1007/s000180050039
35
HipkissA. R.GaunitzF. (2014). Inhibition of tumour cell growth by carnosine: some possible mechanisms.Amino Acids46327–337. 10.1007/s00726-013-1627-5
36
HipkissA. R.BayeE.de CourtenB. (2016). Carnosine and the processes of ageing.Maturitas9328–33. 10.1016/j.maturitas.2016.06.002
37
HoffmannM.Kleine-WeberH.SchroederS.KrügerN.HerrlerT.ErichsenS.et al (2020). SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor.Cell181271–280. 10.1016/j.cell.2020.02.052
38
HoriiY.ShenJ.FujisakiY.YoshidaK.NagaiK. (2012). Effects of L-carnosine on splenic sympathetic nerve activity and tumor proliferation.Neurosci. Lett.5101–5. 10.1016/j.neulet.2011.12.058
39
HoujeghaniS.KheirouriS.FarajiE.JafarabadiM. A. L. (2018). Carnosine supplementation attenuated fasting glucose, triglycerides, advanced glycation end products, and tumor necrosis factor-α levels in patients with type 2 diabetes: a double-blind placebo-controlled randomized clinical trial.Nutr. Res.4996–106. 10.1016/j.nutres.2017.11.003
40
HuangC.WangY.LiX.RenL.ZhaoJ.HuY.et al (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.Lancet395497–506. 10.1016/S0140-6736(20)30183-5
41
IshikawaN.NakamuraK.Izumiyama-ShimomuraN.AidaJ.MatsudaY.AraiT.et al (2016). Changes of telomere status with aging: an update.Geriatr. Gerontol. Int.130–42. 10.1111/ggi.12772
42
JacobsonR.MignemiN.RoseK.O’RearL.SarillaS.HammH. E.et al (2014). The hyperglycemic byproduct methylglyoxal impairs anticoagulant activity through covalent adduction of antithrombin III.Thromb Res.1341350–1357. 10.1016/j.thromres.2014.09.038
43
JainS.KimE. S.KimD.BurrowsD.FeliceM.KimM.et al (2020). Comparative cerebroprotective potential of d- and l-carnosine following ischemic stroke in mice.Int. J. Mol. Sci.21:3053. 10.3390/ijms21093053
44
JarttiL.LangenH.Söderlund-VenermoM.VuorinenT.RuuskanenO.JarttiT. (2011). New respiratory viruses and the elderly.Open Respir. Med. J.561–69. 10.2174/1874306401105010061
45
KamedaM.TeruyaT.YanagidaM.KondohH. (2020). Frailty markers comprise blood metabolites involved in antioxidation, cognition, and mobility.Proc. Natl. Acad. Sci.1179483–9489. 10.1073/pnas.1920795117
46
KaruppanM. K. M.DevadossD.NairM.CandH. S.LakshmanaM. K. (2021). SARS-CoV-2 infection in the central and peripheral nervous system-associated morbidities and their potential mechanism.Mol. Neurobiol.582465–2480. 10.1007/s12035-020-02245-1
47
KawaharaM.SadakaneY.MizunoK.Kato-NegishiM.TanakaK. I. (2020). Carnosine as a possible drug for zinc-induced neurotoxicity and vascular dementia.Int. J. Mol. Sci.21:2570. 10.3390/ijms21072570
48
KawaharaM.TanakaK. I.Kato-NegishiM. (2018). Zinc, carnosine, and neurodegenerative diseases.Nutrients10:147. 10.3390/nu10020147
49
KöppelH.RiedlE.BraunagelM.SauerhoeferS.EhnertS.GodoyP.et al (2011). L-carnosine inhibits high-glucose-mediated matrix accumulation in human mesangial cells by interfering with TGF-β production and signalling.Nephrol. Dial Transplant.263852–3858. 10.1093/ndt/gfr324
50
KorompokiE.GavriatopoulouM.HicklenR. S.Ntanasis-StathopoulosI.KastritisE.FotiouD.et al (2021). Epidemiology and organ specific sequelae of post-acute COVID19: a narrative review.J. Infect.831–16. 10.1016/j.jinf.2021.05.004
51
LenneyJ. F. (1990). Separation and characterization of two carnosine-splitting cytosolic dipeptidases from hog kidney (carnosinase and non-specific dipeptidase).Biol. Chem. Hoppe Seyler.371433–440. 10.1515/bchm3.1990.371.1.433
52
LenneyJ. F.GeorgeR. P.WeissA. M.KuceraC. M.ChanP. W.RinzlerG. S. (1982). Human ando carnosinase: characterization, distinction from cellular carnosinase, and activation by cadmium.Clin. Chim. Acta123221–231. 10.1016/0009-8981(82)90166-8
53
LimS.BaeJ. H.KwonH. S.NauckM. A. (2020). COVID-19 and diabetes mellitus: from pathophysiology to clinical management.Nat. Rev. Endocrinol.131–20. 10.1038/s41574-020-00435-4
54
LiuY.CotillardA.VatierC.BastardJ. P.FellahiS.StévantM.et al (2015). A dietary supplement containing cinnamon, chromium and carnosine decreases fasting plasma glucose and increases lean mass in overweight or obese pre-diabetic subjects: a randomized, placebo-controlled trial.PLoS One10:e0138646. 10.1371/journal.pone.0138646
55
LopachevA. V.AbaimovD. A.FilimonovI. S.KulichenkovaK. N.FedorovaT. N. (2021). An assessment of the transport mechanism and intraneuronal stability of L-carnosine.Amino Acids51:5. 10.1007/s00726-021-03094-5
56
LopachevA. V.KazanskayaR. B.KhutorovaA. V.FedorovaT. N. (2020). An overview of the pathogenic mechanisms involved in severe cases of COVID-19 infection, and the proposal of salicyl-carnosine as a potential drug for its treatment.Eur. J. Pharmacol.886:173457. 10.1016/j.ejphar.2020.173457
57
MaX.VervoortD. (2020). Critical care capacity during the COVID-19 pandemic: global availability of intensive care beds.J. Crit. Care5896–97. 10.1016/j.jcrc.2020.04.012
58
MaX.VervoortD.ReddyC. L.ParkK. B.MakasaE. (2020). Emergency and essential surgical healthcare services during COVID-19 in low- and middle-income countries: a perspective.Int. J. Surg.7943–46. 10.1016/j.ijsu.2020.05.037
59
MacariniJ. R.MaravaiS. G.CararoJ. H.DimerN. W.GonçalvesC. L.KistL. W.et al (2014). Impairment of electron transfer chain induced by acute carnosine administration in skeletal muscle of young rats.Biomed. Res. Int.2014:632986. 10.1155/2014/632986
60
MacedoL. W.CararoJ. H.MaravaiS. G.GonçalvesC. L.OliveiraG. M.KistL. W.et al (2016). Carnosine administration increases respiratory chain complexes and citric acid cycle enzyme activities in cerebral cortex of young rats.Mol. Neurobiol.535582–5590. 10.1007/s12035-015-9475-9
61
MahaseE. (2020). Covid-19: what do we know about “long Covid”?BMJ14:m2815. 10.1136/bmj.m2815
62
MandalS.BarnettJ.BrillS. E.BrownJ. S.DennenyE. K.HareS. S.et al (2020). ‘Long-COVID’: a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following andomized tion for COVID-19.Thorax76396–398. 10.1136/thoraxjnl-2020-215818
63
McFarlandG. A.HollidayR. (1994). Retardation of the senescence of cultured human diploid fibroblasts by carnosine.Exp. Cell Res.212167–175. 10.1006/excr.1994.1132
64
MehtaP.McAuleyD. F.BrownM.SanchezE.TattersallR. S.MansonJ. J. (2020). COVID-19: consider cytokine storm syndromes and immunosuppression.Lancet3951033–1034. 10.1016/S0140-6736(20)30628-0
65
MenonK.CameronJ. D.CourtenM.CourtenB. (2021). Use of carnosine in the prevention of cardiometabolic risk factors in overweight and obese individuals: study protocol for a andomized, double-blind placebo-controlled trial.BMJ11:e043680. 10.1136/bmjopen-2020-043680
66
MorieriM. L.FadiniG. P.BoscariF.FiorettoP.MaranA.BusettoL.et al (2020). Hyperglycemia, glucocorticoid therapy, and outcome of COVID-19.Diabetes Res. Clin. Pract.168:108449. 10.1016/j.diabres.2020.108449
67
MuchaS. R.DugarS.McCraeK.JosephD. E.BartholomewJ.SachaG.et al (2020). Coagulopathy in COVID-19.Cleve Clin. J. Med.87461–468. 10.3949/ccjm.87a.ccc024
68
NagaiK.SudaT. (1998). Realization of spontaneous healing function by carnosina.Methods Find Exp. Clin. Pharmacol.10497–507.
69
OoiT. C.ChanK. M.SharifR. (2020). Zinc L-Carnosine Protects CCD-18co Cells from L-Buthionine Sulfoximine-Induced Oxidative Stress via the Induction of Metallothionein and Superoxide Dismutase 1 Expression.Biol. Trace Elem. Res.198464–471. 10.1007/s12011-020-02108-9
70
PepperE. D.FarrellM. J.NordG.FinkelS. E. (2010). Antiglycation effects of carnosine and other compounds on the long-term survival of Escherichia coli.Appl. Environ. Microbiol.767925–7930. 10.1128/AEM.01369-10
71
PirothL.CottenetJ.MarietA. S.BonniaudP.BlotM.Tubert-BitterP.et al (2020). Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study.Lancet Respir. Med.9251–259. 10.1016/S2213-2600(20)30527-0
72
PollardC. A.MorranM. P.Nestor-KalinoskiA. L. (2020). The COVID-19 pandemic: a global health crisis.Physiol. Genom.52549–557. 10.1152/physiolgenomics.00089.2020
73
PuellesV. G.LütgehetmannM.LindenmeyerM. T.SperhakeJ. P.WongM. N.AllweissL.et al (2020). Multiorgan and renal tropism of SARSCoV-2.N. Engl. J. Med.383590–592. 10.1056/NEJMc2011400
74
RandoH. M.BennettT. D.ByrdJ. B.BramanteC.CallahanT. J.ChuteC. G.et al (2021). Challenges in defining Long COVID: striking differences across literature, electronic health records, and patient-reported information. medRxiv [Preprint] 26:2021. 10.1101/2021.03.20.21253896
75
RasheedH. A.Al-KuraishyH. M.Al-GareebA. I.HussienN. R.Al-NamiM. S. (2019). Effects of diabetic pharmacotherapy on prolactin hormone in patients with type 2 diabetes mellitus: bane or Boon.J. Adv. Pharmaceut. Technol. Res.10163–168. 10.4103/japtr.JAPTR_65_19
76
RennerC.AspergerA.SeyffarthA.MeixensbergerJ.GebhardtR.GaunitzF. (2010). Carnosine inhibits ATP production in cells from malignant glioma.Neurol. Res.32101–105. 10.1179/016164109X12518779082237
77
RodriguezL.PekkarinenP. T.LakshmikanthT.TanZ.ConsiglioC. R.PouC.et al (2020). Systems-level immunomonitoring from acute to recovery phase of severe COVID-19.Cell Rep. Med.1:100078. 10.1016/j.xcrm.2020.100078
78
RubinR. (2020). As their numbers grow, COVID-19 “Long Haulers” stump experts.JAMA3241381–1383. 10.1001/jama.2020.17709
79
SaadahL. M.DeiabG. I. A.Al-BalasQ.BashetiI. A. (2020). Carnosine to Combat Novel Coronavirus (nCoV): molecular Docking and Modeling to Cocrystallized Host Angiotensin-Converting Enzyme 2 (ACE2) and Viral Spike Protein.Molecules25:5605. 10.3390/molecules25235605
80
SahebnasaghA.AvanR.SaghafiF.MojtahedzadehM.SadremomtazA.ArastehO.et al (2020). Pharmacological treatments of COVID-19.Pharmacol. Rep.201–33. 10.1007/s43440-020-00152-9
81
SchönM.MousaA.BerkM.ChiaW. L.UkropecJ.MajidA.et al (2019). The potential of carnosine in brain-related disorders: a comprehensive review of current evidence.Nutrients11:1196. 10.3390/nu11061196
82
Schwank-XuC.ForsbergE.BentingerM.ZhaoA.AnsurudeenI.DallnerG.et al (2021). L-carnosine stimulation of coenzyme Q10 biosynthesis promotes improved mitochondrial function and decreases hepatic steatosis in diabetic conditions.Antioxidants10:793. 10.3390/antiox10050793
83
ScutoM.Trovato SalinaroA.ModafferiS.PolimeniA.PfefferT.WeigandT.et al (2020). Carnosine activates cellular stress response in podocytes and reduces glycative and lipoperoxidative stress.Biomedicines8:177. 10.3390/biomedicines8060177
84
ShahW.HillmanT.PlayfordE. D.HishmehL. (2021). Managing the long term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline.BMJ372:n136. 10.1136/bmj.n136
85
ShaoL.LiQ. H.TanZ. (2004). L-carnosine.Biochem. Biophys. Res. Commun.324931–936. 10.1016/j.bbrc.2004.09.136
86
ShenY.TianY.YangJ.ShiX.OuyangL.GaoJ.et al (2014). Dual effects of carnosine on energy metabolism of cultured cortical astrocytes under normal and ischemic conditions.Regul. Peptides19345–52. 10.1016/j.regpep.2014.08.005
87
SonD. O.SatsuH.KisoY.TotsukaM.ShimizuM. (2008). Inhibitory effect of carnosine on interleukin-8 production in intestinal epithelial cells through translational regulation.Cytokine42265–276. 10.1016/j.cyto.2008.02.011
88
StuerenburgH. J.KunzeK. (1999). Concentrations of free carnosine (a putative membrane-protective antioxidant) in human muscle biopsies and rat muscles.Arch. Gerontol. Geriatr.29107–113. 10.1016/s0167-4943(99)00020-5
89
StvolinskyS.AntipinM.MeguroK.SatoT.AbeH.BoldyrevA. A. (2010). Effect of carnosine and its Trolox-modified derivatives on life span of Drosophila melanogaster.Rejuvenation Res.13453–457. 10.1089/rej.2009.1010
90
TallonM. J.HarrisR. C.MaffulliN.TarnopolskyM. A. (2007). Carnosine, taurine and enzyme activities of human skeletal muscle fibres from elderly subjects with osteoarthritis and young moderately active subjects.Biogerontology8129–137. 10.1007/s10522-006-9038-6
91
TeufelM.SaudekV.LedigJ. P.BernhardtA.BoularandS.CarreauA.et al (2003). Sequence identification and characterization of human carnosinase and a closely related non-specific dipeptidase.J. Biol. Chem.2786521–6531. 10.1074/jbc.M209764200
92
WangF.WangH.FanJ.ZhangY.WangH.ZhaoQ. (2020). Pancreatic injury patterns in patients with coronavirus disease 19 pneumonia.Gastroenterology159367–370. 10.1053/j.gastro.2020.03.055
93
WenW.SuW.TangH.LeW.ZhangX.LiuX.et al (2020). Immune cell profling of COVID-19 patients in the recovery stage by single-cell sequencing.Cell Discov.6:31. 10.1038/s41421-020-0168-9
94
WiersingaW. J.RhodesA.ChengA. C.PeacockS. J.PrescottH. C. (2020). Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review.JAMA324782–793. 10.1001/jama.2020.12839
95
WuZ.McGooganJ. M. (2020). Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention.JAMA3231239–1242. 10.1001/jama.2020.2648
96
XiangJ.HuY.SmithD. E.KeepR. F. (2006). PEPT2-mediated transport of 5-aminolevulinic acid and carnosine in astrocytes.Brain Res.112218–23. 10.1016/j.brainres.2006.09.013
97
YeY.LagnitonP. N. P.YeS.LiE.XuR. H. (2020). COVID-19: what has been learned and to be learned about the novel coronavirus disease.Int. J. Biol. Sci.161753–1766. 10.7150/ijbs.45134
98
YelinD.MargalitI.YahavD.RunoldM.BruchfeldJ. (2020). Long COVID-19-it’s not over until?Clin. Microbiol. Infect.27506–508. 10.1016/j.cmi.2020.12.001
99
YunevaA. O.KramarenkoG. G.VetreshchakT. V.GallantS.BoldyrevA. A. (2002). Effect of carnosine on Drosophila melanogaster lifespan.Bull. Exp. Biol. Med.133559–561. 10.1023/a:1020273506970
100
ZhangQ. L.DingY. Q.HouJ. L.HeL.HuangZ. X.WangH. J.et al (2003). Detection of severe acute respiratory syndrome (SARS)-associated coronavirus RNA in autopsy tissues with in situ hybridization.Acad. J. First Med. Coll. PLA231125–1127.
101
ZhouF.YuT.DuR.FanG.LiuY.LiuZ.et al (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.Lancet3951054–1062. 10.1016/S0140-6736(20)30566-3
Summary
Keywords
carnosine, diabetes, long COVID, SARS-CoV-2 infection, anti-glycating agent
Citation
Diniz FC, Hipkiss AR and Ferreira GC (2022) The Potential Use of Carnosine in Diabetes and Other Afflictions Reported in Long COVID Patients. Front. Neurosci. 16:898735. doi: 10.3389/fnins.2022.898735
Received
17 March 2022
Accepted
18 May 2022
Published
22 June 2022
Volume
16 - 2022
Edited by
Alexandra Latini, Federal University of Santa Catarina, Brazil
Reviewed by
Carlos Henrique Xavier, Federal University of Goiás, Brazil
Updates
Copyright
© 2022 Diniz, Hipkiss and Ferreira.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Gustavo Costa Ferreira, gustavo.ferreira@bioqmed.ufrj.br
This article was submitted to Neuroenergetics, Nutrition and Brain Health, a section of the journal Frontiers in Neuroscience
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.